---
title: "辉瑞达成 105 亿美元的肿瘤学交易，而礼来则在扩展其疫苗业务"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/288199750.md"
description: "辉瑞与信达生物达成了一项价值高达 105 亿美元的协议，预付 6.5 亿美元共同开发 12 个肿瘤学项目。同时，礼来正在收购 Curevo、LimmaTech 和 Vaccine Co.，总价值高达 40 亿美元，以增强其疫苗组合。这些重大交易突显了生物制药领域跨境合作与竞争的加剧，可能加速全球对新治疗方法的获取"
datetime: "2026-06-01T02:05:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288199750.md)
  - [en](https://longbridge.com/en/news/288199750.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288199750.md)
---

# 辉瑞达成 105 亿美元的肿瘤学交易，而礼来则在扩展其疫苗业务

Pfizer's cancer push: Pfizer will pay Innovent $650M upfront in a deal worth up to $10.5B, aiming to co-develop 12 oncology programs and expand its cancer drug pipeline. Lilly's vaccine spree: Eli Lilly will acquire Curevo, LimmaTech, and Vaccine Co. for up to $4B combined, bolstering its position in infectious disease prevention. Global market impact: These transactions signal heightened cross-border collaboration and competition in biopharma, potentially accelerating access to new treatments worldwide.

### 相关股票

- [PFE.US](https://longbridge.com/zh-CN/quote/PFE.US.md)
- [LLY.US](https://longbridge.com/zh-CN/quote/LLY.US.md)
- [01801.HK](https://longbridge.com/zh-CN/quote/01801.HK.md)
- [IBB.US](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [ELIL.US](https://longbridge.com/zh-CN/quote/ELIL.US.md)
- [LLYX.US](https://longbridge.com/zh-CN/quote/LLYX.US.md)
- [XBI.US](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/zh-CN/quote/BIB.US.md)
- [XLV.US](https://longbridge.com/zh-CN/quote/XLV.US.md)
- [IHE.US](https://longbridge.com/zh-CN/quote/IHE.US.md)
- [FBT.US](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [VHT.US](https://longbridge.com/zh-CN/quote/VHT.US.md)
- [SBIO.US](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/zh-CN/quote/ARKG.US.md)
- [LABU.US](https://longbridge.com/zh-CN/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/zh-CN/quote/BBH.US.md)
- [ELIS.US](https://longbridge.com/zh-CN/quote/ELIS.US.md)
- [IBBQ.US](https://longbridge.com/zh-CN/quote/IBBQ.US.md)
- [LABD.US](https://longbridge.com/zh-CN/quote/LABD.US.md)
- [IXJ.US](https://longbridge.com/zh-CN/quote/IXJ.US.md)
- [LLYZ.US](https://longbridge.com/zh-CN/quote/LLYZ.US.md)

## 相关资讯与研究

- [礼来新药 Retatrutide 三期临床成功：40 周减重 15%，降糖效果显著](https://longbridge.com/zh-CN/news/289059238.md)
- [太空经济第一个颠覆的行业，为什么会是医药？](https://longbridge.com/zh-CN/news/289197942.md)
- [阿斯利康加入减肥药赛道：口服药减重 11.8%](https://longbridge.com/zh-CN/news/289144891.md)
- [诺和诺德、礼来争夺 GLP-1 口服药市场](https://longbridge.com/zh-CN/news/289080739.md)
- [贝莱德减持信达生物约 100.21 万股 每股作价约 82.91 港元](https://longbridge.com/zh-CN/news/289047572.md)